Dutch regulators investigate Biogen over MS drug market conduct
Dutch authorities are investigating Biogen for possible abuse of dominance in MS treatments and related blood tests. Senior pharma leaders should note the regulatory risk for firms with strong market positions. Watch for further action from Dutch or EU competition authorities.
US Democrats move to probe Trump-era MFN drug pricing agreements
Democratic committee leaders have begun steps to investigate MFN drug pricing agreements from the Trump administration. This could affect pharma pricing strategies and regulatory risk for manufacturers. Policy changes or further scrutiny may follow.
CFTC prepares charges against Kalshi over product notification failures
The CFTC is investigating Kalshi for failing to notify the agency about dozens of new products. This raises compliance risks for financial exchanges using rapid product launches. Senior leaders should review notification processes as regulatory scrutiny increases.
Trump administration allocates $10B to rural health, weighs Medicaid cuts
The Trump administration has directed $10 billion to rural health, while planning further Medicaid reductions. This move affects state funding and could reshape access to care for insurers and healthcare leaders. Watch for shifts in state-level programmes and future federal decisions.
France accuses Iran of cyberattacks on food and medical cold chains
France has blamed Iran for cyberattacks on thousands of freezer units in supermarkets and blood banks. The incident exposes risks to food safety and medical supply chains. Regulated sectors must review cyber defences for critical infrastructure.
Reddit’s ad credits aim to boost spend as ad revenue growth slows
Reddit is offering seasonal ad credits to attract advertisers after a drop in search referrals and a slowdown in ad revenue growth. Marketing leaders say measurement and proof of year-round impact remain barriers to bigger budgets. Watch for further shifts in advertiser sentiment.
CMS delays Medicare RPM payment halt to 2029 after industry pushback
CMS will continue Medicare payments for third-party remote patient monitoring services until 2029, following industry objections. This gives healthcare providers more time to adapt their virtual care models. Executives should reassess digital health strategies in light of the extension.
Argenx pays $550 million for Unnatural Products’ peptide technology
Argenx will acquire Unnatural Products’ macrocyclic peptide platform for $550 million up front. The deal gives Argenx new tools to develop oral medicines for immune-mediated diseases. Pharma leaders should watch for potential shifts in drug development strategy.
OpenAI sets limits on ad revenue ambitions to protect user privacy
OpenAI’s monetisation chief says privacy rules restrict ad partner requests and distances from the $100 billion ad revenue figure. Senior leaders in regulated sectors should note OpenAI’s stance on user trust over aggressive monetisation. Watch for evolving privacy standards in AI-driven advertising.
WuXi AppTec removed from US Chinese military company list
WuXi AppTec, a major pharma partner, is no longer on the US list of Chinese military companies. This eases some regulatory and geopolitical risk for pharmaceutical firms working with WuXi. Firms should monitor for further US policy shifts.
Berkshire Hathaway spends $9.6bn on buybacks as insurance earnings fall
Berkshire Hathaway bought back $9.6 billion in shares after a 43% drop in insurance underwriting profits. The move signals a shift in capital allocation as operating income fell 5.8%. Insurers and finance leaders should watch for further buybacks and AI bets.
Novartis drug lowers risk marker but fails to cut heart attack rates
Novartis reported that its drug reduced a cardiovascular risk marker but did not lower heart attack or stroke rates. This challenges assumptions in cardiovascular drug development. Pharma leaders may need to reconsider biomarker-based strategies.
BIO challenges US Medicare pilot linking drug prices to peer nations
BIO is joining a legal challenge to a US Medicare pilot that ties drug prices to those in peer countries. This move could affect how pharma firms set prices in the US. Senior leaders should watch for shifts in pricing policy and legal precedent.
Microsoft ends Oracle AI cloud deal as $80B contract review hits suppliers
Microsoft is ending its 2023 deal to rent AI computing from Oracle, declining renewal as it reassesses over $80B in outside cloud contracts. This shift affects AI infrastructure suppliers and signals cost and technology pressures. Watch for further supplier changes.
Democrats’ midterm gains may ease pressure on US hospitals
Democrats are expected to prioritise reversing Medicaid cuts and expanding insurance coverage, according to STAT. This could improve funding stability for healthcare providers. Hospital leaders should watch for regulatory shifts affecting reimbursement and access.
States file new lawsuit to block Trump Medicaid work requirements
States have launched another lawsuit against the Trump administration over Medicaid work requirements, according to STAT. The move signals ongoing legal risk for health insurers and care providers reliant on Medicaid contracts. Watch for further court rulings on implementation.
CMS expands power to revoke Medicare billing for owner misconduct
US regulators can now revoke Medicare billing rights from providers and parent firms that breach federal rules. This raises compliance risks for healthcare groups and investors. Boards should review ownership structures and risk controls.
Fox closes $22 billion Roku deal, reshaping TV and streaming reach
Fox Corp. has closed its $22 billion acquisition of Roku, adding over 100 million streaming households to its digital reach. The deal gives Fox a stronger position in streaming, data, and advertising. Brand and media leaders should watch for shifts in digital ad and content strategies.
Firms face challenge in securing AI agents due to unclear behaviour norms
A new report says companies cannot easily set baselines for AI agent behaviour. This complicates risk management and digital security for regulated firms. Senior leaders should review how they monitor AI-driven processes.
Blackstone and Aon launch Lloyd’s syndicate to expand reinsurance capital
Blackstone and Aon have set up a Lloyd’s of London syndicate, Cortina, to back reinsurance contracts. The move increases capital for property and casualty risk transfer. Senior insurance leaders face new competition and capacity dynamics as alternative asset managers expand.